TPST
Tempest Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 22.2M | — | 389.0K | — | — |
| Gross Profit | (22.2M) | — | (389.0K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 3.0M | 12.6M | 28.5M | 17.5M | 22.5M |
| SG&A Expense | 15.4M | 14.0M | 13.6M | 11.7M | 12.1M |
| General & Admin Expense | 15.4M | 14.0M | 13.6M | 11.7M | 12.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (389.0K) | — | — |
| Total Operating Expenses | 18.5M | 26.6M | 41.6M | 29.2M | 34.6M |
| Cost and Expenses | 40.6M | 26.6M | 42.0M | 29.2M | 34.6M |
| Operating Income (EBIT) | (40.6M) | (26.6M) | (42.0M) | (29.2M) | (34.6M) |
| Non-Operating | |||||
| Interest Income | 147.0K | 520.0K | 1.5M | 1.1M | 549.0K |
| Interest Expense | 23.0K | 207.0K | 1.3M | 1.4M | 1.6M |
| Net Interest Income | 124.0K | 313.0K | 183.0K | (334.0K) | (1.1M) |
| Other Non-Op Income/Expense | 171.0K | 313.0K | 183.0K | (334.0K) | (1.1M) |
| Non-Operating Income (excl Interest) | (164.0K) | (520.0K) | (1.5M) | (1.1M) | (549.0K) |
| EBT (Pre-Tax Income) | (40.5M) | (26.3M) | (41.8M) | (29.5M) | (35.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (40.5M) | (26.3M) | (41.8M) | (29.5M) | (35.7M) |
| Earnings from Cont. Ops | (40.5M) | (26.3M) | (41.8M) | (29.5M) | (35.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (40.5M) | (26.3M) | (41.8M) | (29.5M) | (35.7M) |
| Per Share | |||||
| Basic EPS | ($4.48) | ($6.33) | ($1.50) | ($1.91) | ($3.18) |
| Diluted EPS | ($4.48) | ($6.33) | ($1.50) | ($1.91) | ($3.18) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 15.2M | 4.1M | 27.9M | 15.4M | 888000 |
| Diluted Shares Outstanding | 15.2M | 4.1M | 27.9M | 15.4M | 888378 |
| Profitability Metrics | |||||
| EBITDA | (40.3M) | (25.8M) | (40.1M) | (27.7M) | (33.5M) |
| D&A | 191.0K | 266.0K | 389.0K | 381.0K | 638.0K |
| EBIT | (40.5M) | (26.1M) | (40.5M) | (28.0M) | (34.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026